<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>JUNE 2013</th>
<th>VOLUME 3</th>
<th>NUMBER 6</th>
</tr>
</thead>
</table>

**IN THIS ISSUE**
- Highlighted research articles ......................................... 591

**NEWS IN BRIEF**
- Important news stories affecting the community .................. 594

**NEWS IN DEPTH**
- Q&A: Ashok Venkitaraman on “Undruggable” Targets .............. 597
  - Second Chances for Shelved Compounds ......................... 598

**RESEARCH WATCH**
- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 599

**ONLINE**
- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**IN THIS ISSUE**
- Highlighted research articles ......................................... 591

**NEWS IN BRIEF**
- Important news stories affecting the community .................. 594

**NEWS IN DEPTH**
- Q&A: Ashok Venkitaraman on “Undruggable” Targets .............. 597
  - Second Chances for Shelved Compounds ......................... 598

**RESEARCH WATCH**
- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 599

**ONLINE**
- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**REVIEW**
- Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters In Vivo .................. 616
  - B. Kocher and D. Piwnica-Worms

**RESEARCH BRIEFS**
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas .................. 630
  - See commentary, p. 604
  - Précis: Preliminary data from a prospective phase II trial shows cabozantinib elicits prolonged partial responses and disease stabilization in non-small cell lung cancers harboring RET fusions.

- FGFR Fusions in the Driver’s Seat ......................... 607
  - A.J. Sabnis and T.G. Bivona
  - See article, p. 636
  - Précis: FGFR gene fusions that encode for active kinases are present in multiple cancer types and confer enhanced sensitivity to FGFR inhibitors.

- Extending the Convergence of Canonical WNT Signaling and Classic Cancer Pathways for Treatment of Malignant Peripheral Nerve Sheath Tumors .................. 610
  - K.M. Reilly
  - See article, p. 674
  - Précis: SDH-deficient tumors of various lineages are characterized by a divergent DNA hypermethylation profile comparable to that of other Krebs cycle-defective tumors.

**IN THIS ISSUE**
- Highlighted research articles ......................................... 591

**NEWS IN BRIEF**
- Important news stories affecting the community .................. 594

**NEWS IN DEPTH**
- Q&A: Ashok Venkitaraman on “Undruggable” Targets .............. 597
  - Second Chances for Shelved Compounds ......................... 598

**RESEARCH WATCH**
- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 599

**ONLINE**
- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**IN THIS ISSUE**
- Highlighted research articles ......................................... 591

**NEWS IN BRIEF**
- Important news stories affecting the community .................. 594

**NEWS IN DEPTH**
- Q&A: Ashok Venkitaraman on “Undruggable” Targets .............. 597
  - Second Chances for Shelved Compounds ......................... 598

**RESEARCH WATCH**
- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 599

**ONLINE**
- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**REVIEW**
- Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters In Vivo .................. 616
  - B. Kocher and D. Piwnica-Worms

**RESEARCH BRIEFS**
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas .................. 630
  - See commentary, p. 604
  - Précis: Preliminary data from a prospective phase II trial shows cabozantinib elicits prolonged partial responses and disease stabilization in non-small cell lung cancers harboring RET fusions.

- FGFR Fusions in the Driver’s Seat ......................... 607
  - A.J. Sabnis and T.G. Bivona
  - See article, p. 636
  - Précis: FGFR gene fusions that encode for active kinases are present in multiple cancer types and confer enhanced sensitivity to FGFR inhibitors.

- Extending the Convergence of Canonical WNT Signaling and Classic Cancer Pathways for Treatment of Malignant Peripheral Nerve Sheath Tumors .................. 610
  - K.M. Reilly
  - See article, p. 674
  - Précis: SDH-deficient tumors of various lineages are characterized by a divergent DNA hypermethylation profile comparable to that of other Krebs cycle-defective tumors.

**IN THIS ISSUE**
- Highlighted research articles ......................................... 591

**NEWS IN BRIEF**
- Important news stories affecting the community .................. 594

**NEWS IN DEPTH**
- Q&A: Ashok Venkitaraman on “Undruggable” Targets .............. 597
  - Second Chances for Shelved Compounds ......................... 598

**RESEARCH WATCH**
- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 599

**ONLINE**
- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**IN THIS ISSUE**
- Highlighted research articles ......................................... 591

**NEWS IN BRIEF**
- Important news stories affecting the community .................. 594

**NEWS IN DEPTH**
- Q&A: Ashok Venkitaraman on “Undruggable” Targets .............. 597
  - Second Chances for Shelved Compounds ......................... 598

**RESEARCH WATCH**
- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 599

**ONLINE**
- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**REVIEW**
- Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters In Vivo .................. 616
  - B. Kocher and D. Piwnica-Worms

**RESEARCH BRIEFS**
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas .................. 630
  - See commentary, p. 604
  - Précis: Preliminary data from a prospective phase II trial shows cabozantinib elicits prolonged partial responses and disease stabilization in non-small cell lung cancers harboring RET fusions.

- FGFR Fusions in the Driver’s Seat ......................... 607
  - A.J. Sabnis and T.G. Bivona
  - See article, p. 636
  - Précis: FGFR gene fusions that encode for active kinases are present in multiple cancer types and confer enhanced sensitivity to FGFR inhibitors.

- Extending the Convergence of Canonical WNT Signaling and Classic Cancer Pathways for Treatment of Malignant Peripheral Nerve Sheath Tumors .................. 610
  - K.M. Reilly
  - See article, p. 674
  - Précis: SDH-deficient tumors of various lineages are characterized by a divergent DNA hypermethylation profile comparable to that of other Krebs cycle-defective tumors.

**IN THIS ISSUE**
- Highlighted research articles ......................................... 591

**NEWS IN BRIEF**
- Important news stories affecting the community .................. 594

**NEWS IN DEPTH**
- Q&A: Ashok Venkitaraman on “Undruggable” Targets .............. 597
  - Second Chances for Shelved Compounds ......................... 598

**RESEARCH WATCH**
- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 599

**ONLINE**
- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**IN THIS ISSUE**
- Highlighted research articles ......................................... 591

**NEWS IN BRIEF**
- Important news stories affecting the community .................. 594

**NEWS IN DEPTH**
- Q&A: Ashok Venkitaraman on “Undruggable” Targets .............. 597
  - Second Chances for Shelved Compounds ......................... 598

**RESEARCH WATCH**
- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 599

**ONLINE**
- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**REVIEW**
- Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters In Vivo .................. 616
  - B. Kocher and D. Piwnica-Worms

**RESEARCH BRIEFS**
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas .................. 630
  - See commentary, p. 604
  - Précis: Preliminary data from a prospective phase II trial shows cabozantinib elicits prolonged partial responses and disease stabilization in non-small cell lung cancers harboring RET fusions.

- FGFR Fusions in the Driver’s Seat ......................... 607
  - A.J. Sabnis and T.G. Bivona
  - See article, p. 636
  - Précis: FGFR gene fusions that encode for active kinases are present in multiple cancer types and confer enhanced sensitivity to FGFR inhibitors.

- Extending the Convergence of Canonical WNT Signaling and Classic Cancer Pathways for Treatment of Malignant Peripheral Nerve Sheath Tumors .................. 610
  - K.M. Reilly
  - See article, p. 674
  - Précis: SDH-deficient tumors of various lineages are characterized by a divergent DNA hypermethylation profile comparable to that of other Krebs cycle-defective tumors.
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer........ 658
Précis: MET amplification underlies acquired resistance to cetuximab or panitumumab in colorectal cancers that have not developed secondary KRAS mutations.

Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance ................. 674

GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB ............... 690
D. Bang, W. Wilson, M. Ryan, J.J. Yeh, and A.S. Baldwin
Précis: GSK3α but not GSK3β enhances pancreatic cell growth downstream of mutant KRAS via coordinate activation of both canonical and noncanonical NF-κB signaling.

ON THE COVER
Killian and colleagues found that gastrointestinal stromal tumors (GIST) with mutations in succinate dehydrogenase (SDH) complex genes exhibited a distinct methylation signature relative to the profile of KIT-mutant tumors and normal reference tissues. This methyl-divergent profile was distinguished by increased global DNA hypermethylation, particularly at DNase hypersensitive sites, and was also present in other SDH-mutant tumor lineages, including paraganglioma and pheochromocytoma, supporting the oncogenotype dependence of this signature. In addition, a similarly perturbed methylation profile was detected in gliomas harboring mutations in another Krebs cycle enzyme, isocitrate dehydrogenase (IDH). These findings identify a strong association between the mitochondrial Krebs cycle and cancer epigenomic reprogramming. For details, please see the article by Killian and colleagues on page 648.

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

• Next-Generation Screening Goes National in UK
• Anti-HER2 Drugs May Benefit Some Lung Cancer Patients
• Outreach Cuts Disparities in Colorectal Cancer Deaths
• Debating Drug Approval Decisions
• FDA Struggles with Spending Uncertainties
• Lighting Up Discussion on Tobacco Use

AC icon indicates Author Choice
For more information please visit http://www.aacrjournals.org